[HTML][HTML] Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050 …
KN Moore, M Bookman, J Sehouli, A Miller… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian
Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) …
Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) …
Cyclooxygenase-2 in cervical neoplasia: a review
JL Young, AA Jazaeri, CJ Darus, SC Modesitt - Gynecologic Oncology, 2008 - Elsevier
OBJECTIVE: Previous data demonstrate an association between cyclooxygenase activity
and development of cervical cancer. This review investigates the role of cyclooxygenase-2 …
and development of cervical cancer. This review investigates the role of cyclooxygenase-2 …
[HTML][HTML] Surgical management and postoperative treatment of endometrial carcinoma
JA Lachance, CJ Darus, LW Rice - Reviews in Obstetrics and …, 2008 - ncbi.nlm.nih.gov
Endometrial carcinoma affects over 40,000 American women annually, making it the most
common gynecologic malignancy. Over 80% of disease is diagnosed in the early stages …
common gynecologic malignancy. Over 80% of disease is diagnosed in the early stages …
The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors
KA Atkins, N Arronte, CJ Darus… - The American journal of …, 2008 - journals.lww.com
Background Uterine smooth muscle tumors can usually be divided histologically into
leiomyoma (L) and leiomyosarcoma (LMS). Occasionally, the histologic features are …
leiomyoma (L) and leiomyosarcoma (LMS). Occasionally, the histologic features are …
[HTML][HTML] Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG …
BJ Monk, MW Sill, JL Walker, CJ Darus… - Journal of clinical …, 2016 - ncbi.nlm.nih.gov
Purpose The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-
existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death …
existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death …
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
D Bender, MW Sill, HA Lankes, HD Reyes… - Gynecologic …, 2015 - Elsevier
Purpose Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) …
factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) …
Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation.
X Wang, CJ Darus, BC Xu… - Molecular endocrinology, 1996 - academic.oup.com
To determine whether GH receptor (GHR) cytoplasmic tyrosine residue (s) and tyrosine
phosphorylation are required for signal transduction, we have substituted the eight porcine …
phosphorylation are required for signal transduction, we have substituted the eight porcine …
Development and impact of human papillomavirus vaccines
CJ Darus, JJ Mueller - Clinical obstetrics and gynecology, 2013 - journals.lww.com
Cervical cancer is a global health crisis that disproportionately affects developing nations
and underserved populations. Two vaccines targeting HPV-16 and 18, which account for …
and underserved populations. Two vaccines targeting HPV-16 and 18, which account for …
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent …
V Makker, VL Filiaci, L Chen, CJ Darus, JE Kendrick… - Gynecologic …, 2015 - Elsevier
Objective This two-stage phase II study assessed activity of single agent dalantercept in
patients with recurrent/persistent endometrial carcinoma (EMC). Methods Eligible patients …
patients with recurrent/persistent endometrial carcinoma (EMC). Methods Eligible patients …
[HTML][HTML] Growth hormone promotes the association of transcription factor STAT5 with the growth hormone receptor
BC Xu, X Wang, CJ Darus, JJ Kopchick - Journal of Biological Chemistry, 1996 - ASBMB
Members of the cytokine/growth hormone (GH)/prolactin receptor superfamily transduce
signals by association and activation of JAK tyrosine kinases. For GH receptor (GHR), both …
signals by association and activation of JAK tyrosine kinases. For GH receptor (GHR), both …